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Clinical review
Subarachnoid haemorrhage
Rustam Al-Shahi, Philip M White, Richard J Davenport, Kenneth W Lindsay
Patients with spontaneous (non-traumatic) subarach-
noid haemorrhage usually present first to their general
practitioner. As general practitioners may see only a
few cases during their career, subarachnoid haemor-
rhage can be a diagnostic and management challenge1;
the incidence is about 8 per 100 000 per year.2 The
condition accounts for 3% of patients presenting to
emergency departments with headache3 and around
20 admissions per year to a general hospital covering
300 000 people. The prognosis remains poor: up to
half of patients die and one third of survivors are left
dependent.4 Early treatment can improve outcome5–8;
therefore prompt diagnosis and referral to a neuro-
science unit is important.
How subarachnoid haemorrhage
presents
Patients with subarachnoid haemorrhage usually
present with a characteristic combination of symptoms
(box 1). Sudden severe headache is the cardinal symp-
tom, but it may be the only symptom in up to one third
of patients with aneurysmal subarachnoid haemor-
rhage.12 When patients were asked how long it took for
their headache to reach its maximum severity half of
those with subarachnoid haemorrhage described it as
instantaneous, one fifth said it developed over 1-5 min-
utes, and the rest said it escalated over more than five
minutes.12 The headache usually persists for several
days but may occasionally be much shorter. Even in the
emergency department the positive predictive value of
instantaneous severe headache for aneurysmal sub-
arachnoid haemorrhage is only 39% (95% confidence
interval 29% to 50%),12 so the speed of onset cannot be
relied on to identify all cases of subarachnoid haemor-
rhage.
Although some believe that “sentinel bleeds” or
“warning leaks” precede aneurysmal subarachnoid
haemorrhage, the evidence is that headaches preced-
ing the haemorrhage are rare and do not help in its
diagnosis.14 Overestimation of the importance of senti-
nel bleeds arose from recall bias in hospital based stud-
ies.1 We recommend that the terms sentinel bleeds and
warning leaks should be abandoned: people either
have had a subarachnoid haemorrhage or not and the
important task is to recognise when they have.1 15
Other causes of sudden severe headache
Only about one in four people presenting with sudden
severe headache will have had a subarachnoid
haemorrhage,14 a further 40% will have benign
thunderclap headache,12 and the rest will have other
primary and secondary headache syndromes (box 2).
When sudden severe headache is the only symptom,
one in 10 cases turns out to be subarachnoid haemor-
rhage,14 so the absence of other symptoms cannot be
used to rule out the condition. Conversely, other symp-
toms of subarachnoid haemorrhage (box 1) may
accompany other causes of sudden severe headache
(box 2), so they cannot reliably distinguish subarach-
noid haemorrhage.
Summary points
Subarachnoid haemorrhage should be suspected
in someone with sudden severe headache that
peaks within minutes and lasts more than an hour
Subarachnoid haemorrhage cannot be excluded
by unenhanced computed tomography of the
brain because the sensitivity of the procedure
declines rapidly within hours of symptom onset
When an unenhanced computed tomogram of
the brain is normal, specialist advice should be
sought about subsequent lumbar puncture
When patients are referred to a neuroscience
unit, the referring clinician should specify time
from onset of symptoms, age, comorbidities,
conscious level, and any neurological deficit
Oral nimodipine 60 mg every four hours reduces
poor outcome, but good evidence for other
medical interventions is limited
Endovascular coiling is superseding neurosurgical
clipping for the occlusion of many ruptured
aneurysms
Multidisciplinary follow-up clinics help
manage complications of subarachnoid
haemorrhage
References w1-w14 and ongoing research studies are on
bmj.com
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Investigations for suspected
subarachnoid haemorrhage
Because no clinical feature is sufficiently reliable to
make the diagnosis,12 subarachnoid haemorrhage must
be excluded in anyone presenting with sudden severe
headache that is maximal within minutes, lasts for
more than an hour, and has no alternative explana-
tion.16 Box 3 lists the initial investigations for suspected
subarachnoid haemorrhage.
The ideal investigation for subarachnoid haemor-
rhage is unenhanced computed tomography of the
brain, which needs to be interpreted by an experienced
radiologist and carried out as soon as possible after the
onset of headache (immediately if consciousness is
impaired). Delays in scanning allow subarachnoid
blood time to degrade and increase the possibility of a
tomogram appearing normal. Third generation com-
puted tomography scanners miss about 2% of cases of
subarachnoid haemorrhage within 12 hoursw5 and
about 7% by 24 hours.w6 Subarachnoid blood is almost
completely reabsorbed within 10 days. Changes can be
subtle and interpretation requires expertise (fig 1).
When and how to examine cerebrospinal fluid
Anyone with suspected subarachnoid haemorrhage
and a normal computed tomogram requires a lumbar
puncture.17 Because expertise is required in both the
conduct and the timing of lumbar puncture, as well as
in the interpretation of cerebrospinal fluid results,1 18
we recommend that cases should at least be discussed
with a specialist at a neuroscience unit before the pro-
cedure.
Unless there is any suspicion of an alternative diag-
nosis such as meningitis, we delay lumbar puncture for
at least six hours—preferably 12 hours—after headache
onset. This allows sufficient time for haemoglobin to
degrade into oxyhaemoglobin and bilirubin.19
Bilirubin signifies subarachnoid haemorrhage because
it is only synthesised in vivo, unlike oxyhaemoglobin,
which may result from a traumatic tap or prolonged
storage or agitation of bloodstained cerebrospinal fluid
in vitro.20
The opening pressure of cerebrospinal fluid must
be recorded and samples analysed for protein, cells,
and glucose (paired with a serum sample). To minimise
the risk of oxyhaemoglobin arising in vitro, the last
(least bloodstained) sample of cerebrospinal fluid
should be transported to the laboratory by hand and
centrifuged immediately.21 If there are delays the fluid
should be protected from light to prevent degradation
of bilirubin. Bilirubin causes yellow pigmentation of
the supernatant after centrifugation of cerebrospinal
fluid, known as xanthochromia. Clinicians should use
the naked eye to compare the colour of the cerebro-
spinal fluid supernatant with water against a white
Sources and selection criteria
We searched for relevant articles in Ovid Medline
between 1966 and November 2005 using the search
term subarachnoid haemorrhage. We also searched
the Cochrane Database of Systematic Reviews.5–7 9–11
We have classified the evidence for our treatment
recommendations.w1
Box 1: Presenting symptoms
Sudden death—occurs in 10% of cases of spontaneous
subarachnoid haemorrhage13
Sudden severe headache—maximal immediately or
within minutes, and lasting an hour or more (usually
days)14
Other symptoms of meningism—nausea, vomiting,
photophobia, neck stiffness
Loss of consciousness—transient at onset (around 50%
of cases) or persisting
Epileptic seizures—about 6% of cases
Focal neurological symptoms—dysphasia, hemisensory
or motor symptoms
Box 2: Common causes of sudden severe
headache1 14
• Spontaneous (non-traumatic) subarachnoid
haemorrhage
• Other secondary headache syndromes
Vascular—intracranial venous thrombosis;
intracerebral, intraventricular, extradural, or
subdural haemorrhage; ischaemic stroke; arterial
dissection; vasculitides
Infection—for example, meningitis, encephalitis
Acute hydrocephalus—for example, colloid cyst of
the third ventricle)
Intracranial tumour—including pituitary apoplexy
Intracranial hypotension—spontaneous or after dural
puncture
Metabolic—for example, phaeochromocytoma,
tyramine ingestion with monoamine oxidase
inhibitors
• Primary headache syndromesw2
Thunderclap headache
Migraine
Cluster headache
Headache associated with sexual activity or exertion
Box 3: Initial investigations
Full blood count—anaemia (sickle cell disease),
leucocytosis (after a seizure, systemic infection)
Coagulation screen—underlying coagulopathy
Urea and electrolytes—hyponatraemia is common after
subarachnoid haemorrhage due to salt wasting, not
inappropriate antidiuretic hormone secretion
Serum glucose—hypoglycaemia needs correction,
hyperglycaemia is associated with poor outcome after
subarachnoid haemorrhagew3
Serum magnesium—hypomagnesaemia is common
and associated with poor outcome after subarachnoid
haemorrhagew4
Chest radiography—pulmonary oedema, aspiration
12. lead electrocardiography—cardiac arrhythmia, ST
segment changes, myocardial “stunning”
Unenhanced computed tomography of the brain—as
soon as possible after onset of headache ( < 24 hours)
Lumbar puncture—if an unenhanced computed
tomogram of the brain is normal
Computed tomography angiography—if subarachnoid
haemorrhage is confirmed by computed tomography
or lumbar puncture
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background,22 but every sample should be analysed for
bilirubin using spectrophotometry.21 The estimation of
erythrocyte counts in three consecutive samples of
cerebrospinal fluid does not reliably distinguish
subarachnoid haemorrhage from a traumatic tap.19
Normal computed tomograms and cerebrospinal
fluid samples within days of presentation
If a computed tomogram and cerebrospinal fluid
(including spectrophotometry) are normal within two
weeks of a sudden severe headache, then subarachnoid
haemorrhage is excluded and an alternative diagnosis
must be considered (box 2).
Suspicion of subarachnoid haemorrhage more than
two weeks after onset
The sensitivity of computed tomography for subarach-
noid haemorrhage declines rapidly after 10 days. Xan-
thochromia is only detected in 70% of cases after three
weeks and 40% after four weeks.23 People who present
two or more weeks after a suspected subarachnoid
haemorrhage therefore should be referred urgently to
a neuroscience unit for consideration of further inves-
tigations.
Investigations for the cause of
subarachnoid haemorrhage
Possible causes of subarachnoid haemorrhage deter-
mine further investigations. Three quarters of sponta-
neous cases are due to a ruptured aneurysm, 20% have
no identifiable cause (of which at least half are due to
idiopathic or non-aneurysmal perimesencephalic sub-
arachnoid haemorrhage), and the remainder are
caused by a variety of rare disorders such as
arteriovenous malformations of the brain or spine,
arterial dissection, sympathomimetic drugs, tumours,
or vasculitis.
The pattern of blood on computed tomograms
may suggest the cause. Ruptured aneurysms are most
commonly found on the anterior communicating
artery complex (suggested by blood in the interhemi-
spheric fissure, fig 1C), followed by the internal carotid
artery, middle cerebral artery (blood in the sylvian fis-
sure), and vertebrobasilar circulation. About 20% of
people with subarachnoid haemorrhage have multiple
aneurysms, so the pattern on the computed tomogram
may be crucial to identify which aneurysm has
ruptured. Idiopathic perimesencephalic subarachnoid
haemorrhage is restricted to the perimesencephalic
cistern anterior to the midbrain, but rupture of an
aneurysm in the posterior circulation underlies 5% of
Fig 1 (A) Subarachnoid haemorrhage from right posterior
communicating artery aneurysm with hyperdense or isodense blood
in anterior and posterior basal cisterns (arrow). (B) Blood in
prepontine cistern (arrow). (C) Blood in anterior interhemispheric
fissure (arrow). (D) Blood sedimenting in occipital horns of lateral
ventricles (arrows)
Fig 2 Volume rendered computed tomography angiogram, viewed
from posterior to anterior, showing a 20 mm diameter aneurysm
(solid arrow) at tip of basilar artery (BA) and a 6 mm diameter
aneurysm (dashed arrow) on the left posterior communicating artery.
MCA=left middle cerebral artery; VA=left vertebral artery; AT=atlas
(C1); AX=odontoid process of axis (C2)
Box 4: Complications of aneurysmal
subarachnoid haemorrhage
Rebleeding (without aneurysm occlusion27)
On day 1: 15%
By one month: 40%
After six months: 3% per year
Immediate cerebral ischaemia—due to raised
intracranial pressure and hence reduced cerebral
perfusion pressure
Delayed cerebral ischaemia—peaks between days 4 and
14 after subarachnoid haemorrhage
Hydrocephalus
Seizures
Cardiopulmonary dysfunction—predicted by elevated
cardiac troponin Iw7
Hyponatraemia or hypomagnesaemia—caused by salt
wasting
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this pattern of subarachnoid haemorrhage, so further
investigation is always required.
Multislice CTA (computed tomography angio-
graphy) is our preferred investigation for underlying
causes of spontaneous subarachnoid haemorrhage
because of its speed, tolerability, convenience, and the
ability to provide three dimensional reconstructions
(fig 2). The sensitivity of the procedure for identifying
aneurysms greater than 3 mm diameter is about 96%
but poorer for smaller aneurysms.24 25 We proceed to
four vessel catheter angiography if aneurysmal
subarachnoid haemorrhage is strongly suspected but
the computed tomography angiogram is normal.
Repeated cerebral catheter angiography, spinal cath-
eter angiography, or magnetic resonance imaging may
be necessary to identify alternative causes in some
cases. For people with a purely perimesencephalic dis-
tribution, a normal, good quality computed tomo-
graphy angiogram allows a diagnosis of idiopathic
perimesencephalic subarachnoid haemorrhage with-
out the need for further investigation.19
Outcome after aneurysmal subarachnoid
haemorrhage
Case fatality after aneurysmal subarachnoid haemor-
rhage in the community is 12% and a further 10% of
those who reach hospital alive die within 24 hours. In
population based studies the overall case fatality was
about 50%, which has reduced marginally between
1960 and the mid-1990s.4 Almost all deaths due to
subarachnoid haemorrhage occur within the first three
weeks, most due to rebleeding (box 4). Around one
third of survivors are dependent,4 often with cognitive
impairment,26 and two thirds have a reduced quality of
life.19 26
The three strongest predictors of death or depend-
ence are impaired conscious level on admission,
increasing age, and large volume of blood on initial
computed tomography of the brain. The World
Federation of Neurological Surgeons grading scale
standardises clinical evaluation over time and helps
estimate prognosis (table 1).
Management of aneurysmal
subarachnoid haemorrhage
People with confirmed subarachnoid haemorrhage
should be referred to a neuroscience unit for support-
ive management and interventions directed at prevent-
ing complications (box 4). The specific treatment of
complications such as hydrocephalus, delayed ischae-
mia, or rebleeding is covered elsewhere.28
Best medical management
Frequent checking of the Glasgow coma score and
pupillary responses as well as vigilance for focal neuro-
logical deficits is essential. A drop of just one point in
the Glasgow coma score may be the first sign of a com-
plication. Close monitoring of blood pressure, fluid
balance, heart rhythm, and respiratory function are
crucial because of the risk of cardiac arrhythmia and
pulmonary oedema. Table 2 lists the medical
treatments for aneurysmal subarachnoid haemor-
rhage. Several drugs could plausibly improve outcome,
including magnesium, antiplatelet agents, statins, and
endothelin receptor antagonists (see bmj.com).
When and how should ruptured aneurysms be
secured?
The main purpose of occluding an aneurysm is to pre-
vent rebleeding. Age, World Federation of Neurologi-
cal Surgeons grade, comorbidity, time from onset of
subarachnoid haemorrhage, and the aneurysm’s
vascular anatomy help determine whether interven-
tion is worthwhile and possible.
Although neurosurgical “clipping” became the
standard treatment of aneurysms in the 20th century,
endovascular occlusion of ruptured aneurysms using
detachable coils (“coiling,” fig 3) is now superseding
clipping (grade A, level 1+).6 For aneurysms suitable for
either treatment, coiling confers an absolute risk
reduction over clipping of about 7% (25% relative risk
reduction) for dependency or death at one year, with
benefit sustained to seven years32; the number needed
Table 1 World Federation of Neurological Surgeons grading
scheme for aneurysmal subarachnoid haemorrhagew8
Grade Glasgow coma score Motor deficit*
I 15 Absent
II 13 or 14 Absent
III 13 or 14 Present
IV 7 to 12 —
V 3 to 6 —
*Excludes cranial neuropathies but includes dysphasia.
Table 2 Medical interventions for aneurysmal subarachnoid haemorrhage
Treatment Indication or benefit Evidencew1
Standard practice:
Nimodipine (oral) 60 mg every
four hours for three weeks
Prevention—reduces risk (absolute 5%,
relative 18%) of poor outcome and delayed
cerebral ischaemia
Grade A,5 level 1+
≥3 litres intravenous 0.9% saline
daily
Prevention—sodium depletion and
hypovolaemia contribute to delayed
cerebral ischaemia.29 Monitor fluid balance
and cardiac function
Grade C, level 2+
Analgesia (paracetamol 1 g every
six hours or dihydrocodeine 30
to 60 mg every four hours, or
both
Pain relief —
Graduated compression stockings Prophylaxis against deep vein thrombosis Grade B,30 level 1++
Antiemetics As required —
Stool softeners As required —
Variation in practice:
Intermittent pneumatic
compression
Prophylaxis against deep vein thrombosis Grade B,31 level 1+
Plasma volume expanders Poor evidence for prevention or treatment
of delayed cerebral ischaemia, and
increases complications
Grade B,10 level 1-
Antihypertensives No proved benefit in preventing rebleeding,
and may cause cerebral ischaemiaw9
Grade B,w10 level 1-
Antifibrinolytics No overall benefit because reduction of
rebleeding is offset by more delayed
cerebral ischaemia. Use before aneurysm
occlusion seems more promising, but
evidence is still lackingw11
Grade A,11 level 1++
Antipyretics Temperature >37.5°C Fever associated with
poor outcomew12
Insulin sliding scale or infusion Plasma glucose >11 mmol/l Hyperglycaemia
associated with poor
outcomew3
Magnesium supplementation Plasma magnesium <0.7 mmol/l Hypomagnesaemia
associated with poor
outcomew4, w13
Antiepileptic drugs For treatment (not prophylaxis) of seizures —
Clinical review
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to coil to prevent one poor outcome is 14 (95% confi-
dence interval 10 to 25).6
The evidence for coiling over clipping is influenced
by one large trial, the international subarachnoid
aneurysm trial.32 Those included in the trial were
mostly young and had good World Federation of Neu-
rological Surgeons grades and small anterior circula-
tion aneurysms: this represents half to three quarters
of people with aneurysmal subarachnoid haemor-
rhage33 and reflects the lack of equipoise about most
posterior circulation aneurysms that had already
developed in clinical practice at the time of the trial.
Despite the overall superiority of coiling, complete
aneurysm occlusion was more likely to be achieved
with clipping. Evidence for the durability of coiling
beyond seven years is awaited from the trial.
Aneurysm occlusion tends to be attempted as soon
as practicable (within 3-4 days) after onset of subarach-
noid haemorrhage to prevent rebleeding. Morbidity
seems to occur more often after clipping in the second
week after haemorrhage when the risk of delayed cer-
ebral ischaemia is greatest (grade B, level 1+),7 8
although the timing of coiling does not seem to influ-
ence morbidity related to it (grade C, level 2+).34 Imme-
diate evacuation of some intracerebral haematomas
caused by aneurysm rupture, with concomitant
aneurysm clipping, is supported by one small
randomised trial (grade B, level 1 − ).35
What to do after aneurysmal
subarachnoid haemorrhage
Survivors of subarachnoid haemorrhage need good
advice and information on support groups. Multidisci-
plinary follow-up clinics involving a neurologist,
neurosurgeon, neuroradiologist, and professions allied
to medicine are likely to help identify and manage the
physical and cognitive complications, which often
delay or preclude return to work.26 Tackling modifiable
risk factors for aneurysmal subarachnoid haemor-
rhage is likely to be beneficial in preventing its
recurrence: the most important are smoking, hyper-
tension, and excessive alcohol intake ( > 150 g (19
units) of ethanol per week), each individually
conferring a twofold to threefold increase in risk.36
Only 2% of relatives of people with aneurysmal
subarachnoid haemorrhage are similarly affected, but
the risk is higher when two or more first degree
relatives are affected.37 Familial aggregation is only
partly explained by classic risk factorsw14 and mono-
genic conditions such as adult polycystic kidney
disease. Screening family members for the presence of
unruptured aneurysms may be justifiable when two or
more first degree relatives are affected, taking into
account age, comorbidities, and other risk factors.37
This approach is not supported by evidence from
clinical trials.
Conclusion
People with subarachnoid haemorrhage should be
managed by multidisciplinary teams in specialist
neuroscience units. Future improvements in treatment
of aneurysms and the management of medical compli-
cations of subarachnoid haemorrhage should be tested
in randomised controlled trials. Such research should
improve outcome, which should be monitored in
population based studies or by comprehensive
national audits.33
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Who decides?
Tom had been an active child, enjoying school and
playing football. More importantly, he was a central
part of his family. He was born with an atrioventricular
septal defect and trisomy 21. At that time, intervention
had been thought to be too risky and, as a result, he
had frequent hospital admissions and poor exercise
tolerance. Outcomes and perceptions changed, and, at
7 years old, he underwent surgical repair (pulmonary
vascular resistance was low). This led to four fun years
of walking and playing.
We met him when he was 13 years old, and he was
six months into his ordeal. He had had recurrent
arterial thromboemboli, resulting in occlusion of the
aorta at the bifurcation. After an embolectomy and a
long stay in the paediatric intensive care unit, his
medical problems included renal failure, lower limb
paralysis, and severe back pain. As plans for discharge
were made, with home care and equipment being
organised, he became unwell again. Because of his
recent traumatic experiences, Tom and his family were
not keen on transfer back to intensive care. Optimal
medical therapy was continued.
Tom quickly became withdrawn. He was quiet and
scared. He barely ate or drank. Venepuncture had
made him angry, but this changed: at first he would
cry, and then he just lay still and silent. His sleep was
broken. Up to this point, his mother, brothers, and
certain nurses could easily bring on laughter even
when he was in pain or frustrated.
Although there were no direct discussions with him,
we took his cue. Like other teenagers, he had been
exposed to death, and some of his school friends had
died. His understanding was limited but not poor. For
example, he said that being in intensive care was being
dead and that going back was dying again. From a
medical standpoint, the prognosis for his condition
was undefined and the chances of him surviving the
current acute problem were low. His family faced these
issues with us bravely.
When all his family and friends began arriving and
the needles stopped, he was different. The laughter
returned, as did his appetite for McDonalds. His spirit
returned, and his dislike for wheelchairs did not stop
him going to meet Michael Owen (he did the 30 mile
round trip on a stretcher). His last few days were
happy, and he was surrounded by those he loved.
We remain inspired by Tom and his family.
Jasveer Singh Mangat specialist registrar in paediatric
cardiology (jasveer_mangat@yahoo.com),Priya
Kumar specialist registrar in paediatrics, Guy’s and St
Thomas’ NHS Trust, London
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